A Phase 4 Study of Venetoclax in Combination with Azacitidine in Indian Subjects with Newly Diagnosed Acute Myeloid Leukemia Who are Ineligible for Standard Induction Therapy – RGCI, DELHI
| Protocol Id | PI | Protocol Title | INDICATION | PHASE | Sponsor | CRO/ Other |
| SER-IVO-001 | Dr. Dinesh Bhurani | A Phase IV, Prospective, Open Label, Multi-Centre Study of Ivosidenib Based Therapy in Indian Participants with Isocitrate Dehydrogenase 1 Mutation (mIDH1) positive, previously treated Locally Advanced or Metastatic Cholangiocarcinoma (LA/mCCA) or standard induction chemotherapy ineligible treatment-naïve Acute Myeloid Leukaemia (AML) | AML | IV | Servier India Private Limited | JSS |
| APG2575AG301 | Dr. Narendra Agrawal | A global, multicenter, randomized, double-blind, phase 3 pivotal registrational clinical study of APG-2575 (Lisaftoclax) combined with azacitidine in elderly patients with newly diagnosed acute myeloid leukemia (GLORA-3) | AML | III | Ascentage | IQVIA |
| 2215-MA-3635 | Dr. Dinesh Bhurani | A Post Marketing Surveillance Study on the Safety of Gilteritinib (XOSPATATM 40 mg Tablets) Monotherapy in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FMS-Like Tyrosine Kinase 3 (FLT3) Mutation in India | AML | IV | Astella | IQVIA |